Lymphoseek for Diagnosis and Investigation User Reviews
Are you taking this medicine?
Your review helps others make informed decisions.Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about Lymphoseek (tilmanocept)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: radiologic conjugating agents
- Breastfeeding
"Conducted first exploratory use in June 2013, indication cutaneous melanoma, Breslow/3mm. Tilmanocept was well received by the patient with no local clearance delay, provision <20 min. SLN discovery total <4 min/2 SLN/Path."